Andrew Miller

Company: Apros Therapeutics

Job title: Co-founder & Vice President - Immunology & Operations

Seminars:

Panel Discussion: What is the Best Modality & Delivery Approach to PRR-Pathway Targeting? 1:30 pm

Discussing safety profiles, dosing and scheduling considerations, therapeutic window Dissecting drug design approach for systemic and intratumoral Understanding possible regulatory considerations Mechanisms of action that are leading to strong efficacy Enhancing administration and delivery of therapies for safe and effective clinical outcomes Systemic delivery technologies vs intra-tumoral delivery technologiesRead more

day: Day Two

Oral Administration of Tissue-Targeted TLR7 Agonists for Immune Oncology 4:30 pm

Unpicking the mechanistic studies of our tissue-targeted approaches, Exploring the preclinical models Assessing cytokine responses as it pertains to tissue distribution and residence timeRead more

day: Day One